Augmenting Both Arms of a Randomized Controlled Trial Using External Data: An Application of the Propensity Score-Integrated Approaches
暂无分享,去创建一个
Chenguang Wang | R. Tiwari | Heng Li | Nelson Lu | Yunling Xu | Wei-Chen Chen | Changhong Song | L. Yue*
[1] Heng Li,et al. Propensity score-integrated composite likelihood approach for augmenting the control arm of a randomized controlled trial by incorporating real-world data , 2020, Journal of biopharmaceutical statistics.
[2] Nelson Lu,et al. Some Considerations on Design and Analysis Plan on a Nonrandomized Comparative Study Using Propensity Score Methodology for Medical Device Premarket Evaluation , 2020, Statistics in Biopharmaceutical Research.
[3] Heng Li,et al. Propensity score-integrated composite likelihood approach for incorporating real-world evidence in single-arm clinical studies , 2019, Journal of biopharmaceutical statistics.
[4] Heng Li,et al. Propensity score-integrated power prior approach for incorporating real-world evidence in single-arm clinical studies , 2019, Journal of biopharmaceutical statistics.
[5] Yunling Xu,et al. Good statistical practice in utilizing real-world data in a comparative study for premarket evaluation of medical devices , 2019, Journal of biopharmaceutical statistics.
[6] Nelson Lu,et al. A Study Design for Augmenting the Control Group in a Randomized Controlled Trial: A Quality Process for Interaction Among Stakeholders , 2019, Therapeutic Innovation & Regulatory Science.
[7] Gregory Campbell,et al. Utilizing national and international registries to enhance pre-market medical device regulatory evaluation , 2016, Journal of biopharmaceutical statistics.
[8] Heng Li,et al. A Note on Good Practice of Objective Propensity Score Design for Premarket Nonrandomized Medical Device Studies with an Example , 2016 .
[9] Joseph G Ibrahim,et al. The power prior: theory and applications , 2015, Statistics in medicine.
[10] Yunling Xu,et al. Designing Premarket Observational Comparative Studies Using Existing Data as Controls: Challenges and Opportunities , 2014, Journal of biopharmaceutical statistics.
[11] P. Austin. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples , 2009, Statistics in medicine.
[12] J. Ibrahim,et al. Power prior distributions for regression models , 2000 .
[13] D. Rubin,et al. Reducing Bias in Observational Studies Using Subclassification on the Propensity Score , 1984 .
[14] D. Rubin,et al. The central role of the propensity score in observational studies for causal effects , 1983 .
[15] J. Chemali,et al. Summary and discussion of “ The central role of the propensity score in observational studies for causal effects , 2014 .
[16] N. Reid,et al. AN OVERVIEW OF COMPOSITE LIKELIHOOD METHODS , 2011 .
[17] Henry F. Inman,et al. The overlapping coefficient as a measure of agreement between probability distributions and point estimation of the overlap of two normal densities , 1989 .